| Autor: |
Cooper, S. J., Tweed, J., Raniwalla, J., Butler, A., Welch, C. |
| Předmět: |
|
| Zdroj: |
Acta Psychiatrica Scandinavica; Mar2000, Vol. 101 Issue 3, p218-225, 8p |
| Abstrakt: |
Objective: The aim of this study was to evaluate the efficacy of zotepine in the treatment of acute episodes of schizophrenia. Method: Patients with acute exacerbation of schizophrenia (DSM-III-R criteria; n = 158) were allocated on a random, double-blind basis to receive zotepine (150 or 300 mg/day), chlorpromazine (300 or 600 mg/day) or placebo for 8 weeks. Symptoms were assessed on the BPRS, SANS and CGI scales at baseline and weeks 1, 2, 4, 6 and 8 and patients were assessed at these times for adverse effects. Analysis was by analysis of variance on the intent-to-treat population, with last observation carried forward. Results: Mean BPRS scores improved statistically significantly more with zotepine than chlorpromazine (point estimate of difference -12.4, 95% CI - 18.3 to -6.5) or placebo (point estimate of difference - 12.7, 95% CI -18.6 to -6.8). Zotepine produced significantly fewer extrapyramidal symptoms (EPS) than chlorpromazine. Conclusion: Zotepine is an effective antipsychotic with low propensity for EPS. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
